epocrates logo
epocrates logo
epocrates logo
  • Home
  • Search
  • Tools
  • Saved
  • 0
    Notifications
  • CME
  • Help & Feedback
  • About Us
  • Business Solutions

The clinical information you need, at your fingertips.

Medical News for You

PLoS One

2h

Bed-sharing with dogs not tied to worse sleep

Some owners are convinced their dogs disturb their nights, but what an activity monitor recorded in their own homes told a more complicated story. . .

Front Pain Res

7h

Favorite music lowered pain of IV insertion

A track designed to relax did nothing for patients waiting on a needle, which suggests what is playing may be what matters. . .

Cochrane Database Syst Rev

1d

Drug company gifts carry influence over prescribing

Clinicians commonly believe small perks leave their judgment untouched, but a recent review suggests otherwise. . .

AHA Hypertension 2026

1d

Hidden high blood pressure at home linked to more falls in older adults

Older adults with masked hypertension faced substantially higher fall risk despite normal clinic blood pressure readings. . .

JAMA Netw Open

1d

Hidden steroids found in popular skin creams

One in three targeted over-the-counter products contained an undisclosed prescription-strength corticosteroid. . .

Company news

1d

Long-acting Cabenuva outperforms daily oral therapy in unsuppressed HIV

Six-month CROWN findings suggest injections could expand treatment options for people who have not achieved viral suppression. . .

J Hepatol

1d

Resmetirom or semaglutide for MASH? New guidance helps clinicians choose

Updated European recommendations clarify who qualifies, which drug to prioritize, and when to reassess treatment. . .

AHA Hypertension 2026

1d

Is the DASH diet safe for patients on potassium-raising drugs?

A pooled analysis found no link between potassium-rich DASH groceries and hyperkalemia among Black adults taking medications that can raise potassium. . .

JAMA Netw Open

1d

Oral semaglutide caught on quickly after obesity approval

Real-world data suggest the first oral GLP-1 receptor agonist approved for obesity rapidly entered clinical practice, with many users new to GLP-1 therapy. . .

Trending icon

TRENDING THIS WEEK

learn more about epocrates plus

Clinical FAQs

Check out the answers to frequently asked questions about our clinical content.

About Us

Features

Business Solutions

Help & Feedback

Terms of Use

Privacy Policy

visit epocrates on instagram
visit epocrates on facebook
visit epocrates on youtube
visit epocrates on twitter
visit epocrates on linkedIn

© 2026 epocrates, Inc.

download epocrates on app storedownload epocrates on google play

Do not sell or share my personal information

Download Epocrates from the App StoreDownload Epocrates from the Play Store
About UsFeaturesBusiness SolutionsHelp & FeedbackCookie Preferences
© 2026 epocrates, Inc.   Terms of UsePrivacy PolicyEditorial PolicyDo Not Sell or Share My Information